1-3 of 3
seals (animal)
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Age and Time to Progression Predict Overall Survival (OS) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Who Progress Following Frontline Immunochemotherapy (IC)

Matthew J. Maurer, MS, Lasse H. Jakobsen, PhD, Norbert Schmitz, MD, Umar Farooq, MD, Christopher R. Flowers, MD MS, Peter de Nully Brown, MD PhD, Carrie A. Thompson, MD, Henrik Frederiksen, MD Prof, David Cunningham, MD FRCP, FMedSci, Judit Jørgensen, MD PhD, Viola Poeschel, MD, Grzegorz Nowakowski, MD, John F. Seymour, MBBS, PhD FRACP, Francesco Merli, MD, Corinne Haioun, MD PhD, Herve Ghesquieres, MD PhD, Marita Ziepert, PhD, Herve Tilly, MD PhD, Gilles Salles, MD PhD, Qian Shi, PhD, Tarec Christoffer C. El-Galaly, MD, Thomas M. Habermann, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 400.
https://doi.org/10.1182/blood-2019-124017
Published: 2019
Journal Articles

Evaluation of Progression-Free Survival (PFS) As a Surrogate Endpoint for Overall Survival (OS) in First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): Findings from the Surrogate Endpoint in Aggressive Lymphoma (SEAL) Analysis of Individual Patient Data from 7507 Patients

Qian Shi, PhD, Norbert Schmitz, MD, PhD, Christopher Flowers, MD MS, Fang-Shu Ou, PhD, David Cunningham, Michael Pfreundschuh, MD, John F Seymour, Ulrich Jaeger, Thomas M. Habermann, MD, Corinne Haioun, MD PhD, Hervé Tilly, MD PhD, Herve Ghesquieres, MD PhD, Francesco Merli, Marita Ziepert, Raoul Herbrecht, MD, Jocelyne Flament, MD, Tommy Fu, PhD, Bertrand Coiffier, MD PhD, Daniel Sargent, PhD
Journal: Blood
Blood (2016) 128 (22): 4196.
https://doi.org/10.1182/blood.V128.22.4196.4196
Published: 2016
Journal Articles

Utility of Progression-Free Survival at 24 Months (PFS24) to Predict Subsequent Outcome for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Enrolled on Randomized Clinical Trials: Findings from a Surrogate Endpoint in Aggressive Lymphoma (SEAL) Analysis of Individual Patient Data from 5853 Patients

Matthew J Maurer, MS, Thomas M. Habermann, MD, Qian Shi, PhD, Norbert Schmitz, MD, PhD, David Cunningham, Michael Pfreundschuh, MD, PhD, John F. Seymour, MD, Ulrich Jaeger, Corinne Haioun, MD PhD, Hervé Tilly, MD PhD, Herve Ghesquieres, MD PhD, Francesco Merli, Marita Ziepert, Raoul Herbrecht, MD, Jocelyne Flament, MD, Tommy Fu, PhD, Christopher Flowers, MDMS, Fang-Shu Ou, PhD, Daniel Sargent, PhD, Bertrand Coiffier, MD PhD
Journal: Blood
Blood (2016) 128 (22): 3027.
https://doi.org/10.1182/blood.V128.22.3027.3027
Published: 2016